Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064550 | 0.92 | LMNA (0.47) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2440388 | 0.91 | LMNA (0.52) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL7063863 | 0.89 | LMNA (0.51) | LMNAALDH1A1CSNK2A2CSNK2A1L3MBTL1 | |
| SCHEMBL7063685 | 0.89 | LMNA (0.51) | LMNAALDH1A1CSNK2A2CSNK2A1L3MBTL1 | |
| SCHEMBL7063733 | 0.88 | ALDH1A1 (0.43) | SMN1; SMN2NPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL7062253 | 0.80 | KDM4E (0.36) | LMNANPC1ALDH1A1HPGDMEN1 | |
| SCHEMBL7052872 | 0.78 | ADORA2A (0.44) | TP53ALDH1A1MAPK1CSNK2A1CYP1A2 | |
| SCHEMBL3825844 | 0.75 | LMNA (0.41) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL18325610 | 0.73 | XDH (0.50) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL18325718 | 0.72 | MAT2A (0.37) | LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166606-A1 | 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients | KOLON INDUSTRIES, INC. (KR) | 2003-09-04 | — | — | US | disclosed |
| EP-1311524-A2 | 5'-DEOXY-N-(SUBSTITUTED OXYCARBONYL)-5-FLUOROCYTOSINE AND DERIVATIVES THEREOF, METHOD OF PREPARING SAME, AND ANTICANCER COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENTS | Kolon Industries, Inc. (KR) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002011668-A2 | 5'-DEOXY-N-(SUBSTITUTED OXYCARBONYL)-5-FLUOROCYTOSINE AND DERIVATIVES THEREOF, METHOD OF PREPARING SAME, AND ANTICANCER COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENTS | KOLON INDUSTRIES, INC. (KR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166606-A1 | 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients | DUT, RNGTT, MTAP | LMNA 3178/4885SMN1; SMN2 3982/4885TP53 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.